| ASCENDIS PHARMA AS Patent applications |
| Patent application number | Title | Published |
|---|
| 20120058084 | Interferon Alpha Carrier Prodrugs - The present invention relates to a pharmaceutical composition comprising a water-soluble polymeric carrier linked prodrug of interferon alpha, wherein the prodrug is capable of releasing free interferon alpha, wherein the release half life under physiological conditions is at least 4 days. The invention further relates to prodrugs for said pharmaceutical composition and their use for treating, controlling, delaying or preventing a condition that can benefit from interferon alpha treatment, such as hepatitis C. | 03-08-2012 |
| 20110223230 | HYDROGEL FORMULATIONS - A polymeric prodrug composition including a hydrogel, a biologically active moiety and a reversible prodrug linker. The prodrug linker covalently links the hydrogel and the biologically active moiety at a position and the hydrogel has a plurality of pores with openings on its surface. The diameter of the pores is larger than that of the biologically active moiety at least at all points of the pore between at least one of the openings and the position of the biologically active moiety. | 09-15-2011 |
| 20110172390 | Protein-Proteophore Complexes - The application relates to a composition comprising a hyperbranched polymer attached to a core and a biologically active moiety. The biologically active moiety is attached to the core by means of a substantially non-enzymatically cleavable linker L. The composition can be used to deliver the biologically active moiety to its target. | 07-14-2011 |
| 20110112021 | PEGYLATED RECOMBINANT HUMAN GROWTH HORMONE COMPOUNDS - A chemically modified human Growth Hormone (rhGH) prepared by attaching a transient linker which comprises a polyethylene glycol. The chemically modified protein may have a much longer lasting rhGH activity than that of the unmodified rhGH, enabling reduced dose and scheduling opportunities and the modified rhGH may not cause lipoatrophy. Also includes methods of use for the treatment and/or prevention of diseases or disorders in which use of growth hormone is beneficial. | 05-12-2011 |
| 20110053848 | PRODRUG COMPRISING A DRUG LINKER CONJUGATE - The present invention relates to a prodrug or a pharmaceutically acceptable salt thereof comprising a drug linker conjugate D-L, wherein -D is an amine containing biologically active moiety; and -L is a non-biologically active linker moiety -L | 03-03-2011 |
